Locteron Phase 2b Clinical Plan

In 2009, we plan to initiate a 100-patient Phase 2b clinical trial (SELECT-2) in United States and Europe comparing three doses of Locteron in combination with ribavirin against a control arm treated with a currently marketed interferon alfa in combination with ribavirin. Patients will be treated for 48 weeks with a 24-week follow-up period. The results after 12 weeks of treatment with Locteron will be evaluated and will be the basis for dose selection for Phase 3 clinical trials.

Return to top